Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology, has appointed Michael D. Patten as Chief Strategy Officer. Patten will be based in the United States and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

Patten will be responsible for formulating and overseeing the global corporate development and growth strategy for the company. He will also serve as the Head of Global Alliance, leading efforts to manage and strengthen Harbour BioMed’s global strategic partnerships, with a particular focus on high-potential markets outside of China. 

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: “Michael’s academic background and extensive experience align perfectly with our strategic direction. I am confident that with Michael’s expertise, we will further expand our global footprint and enhance the visibility and impact of Harbour BioMed.”

Patten brings extensive experience and a strong track record in the biopharmaceutical industry. He held a tenure at Bristol Myers Squibb, serving in several key leadership roles. Most recently, as Head of Equity & Venture Capital. 

Prior, he held roles of increasing seniority in Business Development and Alliance Leadership, executing transactions and managing multiple early- and late-stage business development alliances.